Urological Research

, Volume 25, Issue 1, pp 31–34

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer


  • E. C. de Boer
    • Department of UrologyUniversity of Amsterdam
  • L. Somogyi
    • Department of UrologyPécs University, Medical School
  • G. J. W. de Ruiter
    • Department of UrologyUniversity of Amsterdam
  • Th. M. de Reijke
    • Department of UrologyUniversity of Amsterdam
  • K. -H. Kurth
    • Department of UrologyUniversity of Amsterdam
  • D. H. J. Schamhart
    • Department of UrologyUniversity of Amsterdam
Original Papers

DOI: 10.1007/BF00941903

Cite this article as:
de Boer, E.C., Somogyi, L., de Ruiter, G.J.W. et al. Urol. Res. (1997) 25: 31. doi:10.1007/BF00941903


In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guérin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the neutrophil-attracting cytokine interleukin-8 (IL-8). The appearance of IL-8 in patients' urine after BCG therapy was compared with BCG-induced IL-6 and IL-2 and the stability of IL-8 in urine was tested. Compared to IL-6 and IL-2, a rapid induction of IL-8 was observed, occurring after the first BCG instillation. Urinary IL-8 was highly stable, even after 24 h incubation at 37°C. The IL-8 concentration after the first instillation seemed to be associated with subsequent development of an immune response. Consequently, IL-8 seems an attractive candidate for investigation of its prognostic value for a clinical response to BCG therapy.

Key words

Interleukin-8Bacillus Calmette-GuérinBladder carcinomaUrine

Copyright information

© Springer-Verlag 1997